远程医疗公司Hims & Hers Health (HIMS.US)公布2024年第四季度业绩。数据显示，该公司Q4营收同比增长95%至4.81亿美元，好于市场预期的4.7亿美元;每股收益为11美分，也好于市场预期的10美分。

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

但当 HIMS 在 12 月 6 日达到其最后一个波动高点时（使用收盘价），该股的收盘价为 34.23 美元，仅比其 50 天移动平均线 23.29 美元高出 47%。同样，其 2024 年 6 月 18 日的波动高点比当时的 50 天移动平均线高出 ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.